MedTrace Logo

The Management of Pilonidal Wounds With ACell MicroMatrix® and Cytal® Wound Matrix: A Case Series

NCT04041037 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2021-04-20

Study results available
· View outcomes & findings →

Summary

A case series involving the concomitant use of MicroMatrix® and Cytal® Wound Matrix 2-Layer with standard of care negative pressure wound therapy (NPWT) during the management of pilonidal wound healing.

Conditions

  • Pilonidal Disease

Interventions

DEVICE

Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix

Porcine-derived extracellular matrix will be used in powder and 2-Layer wound sheet form in masses up to 1000 mg. Each product is intended for a one-time use only.

Sponsors & Collaborators

  • Integra LifeSciences Corporation

    lead INDUSTRY

Principal Investigators

  • Haane Massarotti, MD · Florida Hospital Tampa

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-26
Primary Completion
2019-08-30
Completion
2019-11-05
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04041037 on ClinicalTrials.gov